Arrowhead Pharmaceuticals: Progress During Adverse Market Conditions

Core Insights - Arrowhead Pharmaceuticals (NASDAQ: ARWR) reported fiscal Q1 2025 results and provided a pipeline update, highlighting the return of zodasiran to clinical trials for treating a rare disease known as HoFH [2] Group 1 - The company has a model portfolio consisting of 15-20 names that are updated regularly, along with a top picks list of up to 10 stocks expected to perform well in the current calendar year [2] - The focus is on attractive risk/reward situations, with trading ideas targeting both short-term and medium-term moves [2]